Welcome to our dedicated page for Gerresheimer news (Ticker: GRRMY), a resource for investors and traders seeking the latest updates and insights on Gerresheimer stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gerresheimer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gerresheimer's position in the market.
Summary not available.
Gerresheimer AG reported a strong start to 2021, achieving revenues of EUR 303 million in Q1, a 3.1% increase year-on-year. Growth was driven by the Plastics & Devices Division, with a notable demand for syringes and pharmaceutical packaging. Adjusted EBITDA rose to EUR 54 million, reflecting a 29.3% year-on-year increase in adjusted earnings per share at EUR 0.57. The company forecasts mid single-digit revenue growth for 2021 and aims for an adjusted EBITDA margin of 22-23%. Gerresheimer is expanding production for Covid-19 vaccine vials, reinforcing its role in the pandemic response.
FAQ
What is the current stock price of Gerresheimer (GRRMY)?
What is the market cap of Gerresheimer (GRRMY)?
